Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Net Income towards Common Stockholders (2019 - 2025)

Silo Pharma's Net Income towards Common Stockholders history spans 7 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders fell 19.55% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$5.1 million, down 36.7%, while the annual FY2024 figure was -$4.4 million, 6211.61% down from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$1.1 million at Silo Pharma, up from -$1.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $6.4 million in Q3 2021 and bottomed at -$2.3 million in Q1 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$1.0 million (2023), against an average of -$720219.5.
  • The largest YoY upside for Net Income towards Common Stockholders was 1107.44% in 2021 against a maximum downside of 877.36% in 2021.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$1.1 million in 2021, then crashed by 52.63% to -$1.7 million in 2022, then surged by 36.72% to -$1.1 million in 2023, then crashed by 64.57% to -$1.7 million in 2024, then skyrocketed by 35.84% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Net Income towards Common Stockholders are -$1.1 million (Q3 2025), -$1.2 million (Q2 2025), and -$1.0 million (Q1 2025).